Intellia's Lonvo-z Shows Three-Year Durability in HAE Trials
Event summary
- Intellia presented four posters at AAAAI 2026 showing long-term data for Lonvo-z (NTLA-2002) in HAE patients.
- 32 patients in Phase 1/2 trials showed 96% reduction in HAE attacks with a one-time 50 mg dose, with 97% attack-free for up to 3 years.
- 86% of 28 patients were attack-free and LTP-free for over 6 months post-treatment.
- Quantitative modeling suggested an 85% reduction in prekallikrein could normalize kallikrein and bradykinin levels.
- Lonvo-z has received multiple regulatory designations, including Orphan Drug and RMAT from the FDA.
The big picture
Intellia's data reinforces the potential of CRISPR-based therapies to transform HAE treatment from chronic management to single-dose cures. The durability of Lonvo-z's effects positions it as a potential market leader, though regulatory hurdles and patient adoption rates remain critical. The broader biotech sector is watching as gene editing technologies move closer to mainstream clinical use.
What we're watching
- Regulatory Pathway
- Whether Lonvo-z can secure full approvals based on Phase 3 HAELO trial data and prior designations.
- Market Adoption
- The pace at which HAE patients and physicians transition from chronic medications to one-time gene editing therapies.
- Competitive Positioning
- How Intellia differentiates Lonvo-z against emerging HAE treatments from competitors like BioCryst and Pharvaris.
Related topics